In this multicenter study the Authors evaluated long-term disability in patients with pediatric-onset MS treated with monoclonal antibodies before age 18 compared with those who initiated these therapies in adulthood.
They found that commencing high-efficacy monoclonal antibody therapy in childhood is associated with more favorable long-term disability outcomes than delayed initiation in adulthood.
See the full text here: https://www.neurology.org/doi/10.1212/WNL.0000000000218056